Susquehanna Advisors Group Inc. Buys Shares of 184,200 Adaptive Biotechnologies Corporation $ADPT

Key Points

• Susquehanna Advisors Group acquired 184,200 shares of Adaptive Biotechnologies worth approximately $3.95 million, while institutional investors collectively own 99.17% of the company.
• Adaptive reported quarterly revenue of $71.55 million, up 21.5% year over year and above estimates, but its loss of $0.25 per share exceeded analysts’ expected loss of $0.13.
• Analysts remain broadly positive, with a consensus “Moderate Buy” rating and an average price target of $24.42; however, insiders sold more than 2 million shares worth $46.7 million over the past 90 days.

Susquehanna Advisors Group Inc. purchased a new position in shares of Adaptive Biotechnologies Corporation (NASDAQ:ADPT - Free Report) in the second quarter, according to the company in its most recent disclosure with the SEC. The institutional investor purchased 184,200 shares of the company's stock, valued at approximately $3,951,000. Susquehanna Advisors Group Inc. owned 0.12% of Adaptive Biotechnologies at the end of the most recent quarter.

Several other large investors have also made changes to their positions in ADPT. 1492 Capital Management LLC bought a new stake in Adaptive Biotechnologies during the fourth quarter worth $1,484,000. Jupiter Asset Management Ltd. boosted its holdings in shares of Adaptive Biotechnologies by 33.8% in the 4th quarter. Jupiter Asset Management Ltd. now owns 362,811 shares of the company's stock valued at $5,892,000 after purchasing an additional 91,683 shares in the last quarter. Westfield Capital Management Co. LP bought a new position in shares of Adaptive Biotechnologies in the 4th quarter valued at $65,942,000. Rhenman & Partners Asset Management AB increased its stake in shares of Adaptive Biotechnologies by 22.2% in the 4th quarter. Rhenman & Partners Asset Management AB now owns 605,000 shares of the company's stock valued at $9,825,000 after purchasing an additional 110,000 shares during the last quarter. Finally, Wasatch Advisors LP acquired a new position in shares of Adaptive Biotechnologies during the 2nd quarter worth $12,361,000. Institutional investors and hedge funds own 99.17% of the company's stock.

Adaptive Biotechnologies Price Performance

Shares of ADPT opened at $25.19 on Monday. The company has a debt-to-equity ratio of 2.22, a quick ratio of 4.68 and a current ratio of 4.79. Adaptive Biotechnologies Corporation has a 52 week low of $12.00 and a 52 week high of $26.87. The stock has a market capitalization of $4.02 billion, a price-to-earnings ratio of -61.44 and a beta of 2.08. The stock has a fifty day moving average of $22.92 and a 200-day moving average of $17.66.

Adaptive Biotechnologies (NASDAQ:ADPT - Get Free Report) last issued its quarterly earnings data on Wednesday, July 29th. The company reported ($0.25) earnings per share for the quarter, missing analysts' consensus estimates of ($0.13) by ($0.12). Adaptive Biotechnologies had a negative return on equity of 36.81% and a negative net margin of 20.73%.The firm had revenue of $71.55 million for the quarter, compared to the consensus estimate of $65.44 million. During the same quarter in the prior year, the firm earned ($0.17) EPS. The company's revenue was up 21.5% on a year-over-year basis. As a group, sell-side analysts anticipate that Adaptive Biotechnologies Corporation will post -0.4 earnings per share for the current fiscal year.

Insider Activity

In other news, insider Susan Bobulsky sold 3,000 shares of the company's stock in a transaction that occurred on Monday, August 10th. The stock was sold at an average price of $25.00, for a total value of $75,000.00. Following the completion of the transaction, the insider owned 396,989 shares of the company's stock, valued at $9,924,725. This represents a 0.75% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Harlan S. Robins sold 492,400 shares of the firm's stock in a transaction that occurred on Tuesday, July 21st. The shares were sold at an average price of $21.89, for a total transaction of $10,778,636.00. Following the completion of the transaction, the insider owned 812,058 shares of the company's stock, valued at approximately $17,775,949.62. This trade represents a 37.75% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders sold 2,062,325 shares of company stock valued at $46,659,069. 5.70% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

ADPT has been the subject of several recent analyst reports. Guggenheim upped their price objective on Adaptive Biotechnologies from $22.00 to $25.00 and gave the stock a "buy" rating in a research report on Thursday, July 30th. Morgan Stanley lifted their target price on Adaptive Biotechnologies from $20.00 to $22.00 and gave the company an "equal weight" rating in a research report on Thursday, July 30th. BTIG Research boosted their target price on Adaptive Biotechnologies from $24.00 to $25.00 and gave the stock a "buy" rating in a research note on Thursday, July 30th. TD Cowen increased their target price on shares of Adaptive Biotechnologies from $25.00 to $28.00 and gave the stock a "buy" rating in a report on Thursday, July 30th. Finally, Piper Sandler raised their price target on shares of Adaptive Biotechnologies from $20.00 to $27.50 and gave the company an "overweight" rating in a research note on Tuesday, August 4th. Five investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $24.42.

Adaptive Biotechnologies Company Profile

Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.

The company's flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source